---
schema_version: "secwatch.filing_event.v1"
accession: "0001006837-26-000019"
form_type: "8-K"
ticker: "VATE"
cik: "0001006837"
company_name: "INNOVATE Corp."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:04:51.057250+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# INNOVATE's MediBeacon receives CE Mark for TGFR Monitor and Reusable Sensor under EU MDR

## Summary
- MediBeacon (equity method investment of INNOVATE) obtained EU CE Mark under MDR for TGFR Monitor and Reusable Sensor.
- Devices are Class IIa; TGFR System enables transdermal assessment of kidney function (tGFR).
- CE Mark allows potential use in European clinical trials; Lumitrace injection approved in U.S. and China.
- Dr. Lui Forni plans to include transdermal GFR in his clinical research in Europe later this year.

## SEC filing metadata
- accession: 0001006837-26-000019
- form_type: 8-K
- ticker: VATE
- cik: 0001006837
- company_name: INNOVATE Corp.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006837/000100683726000019/0001006837-26-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006837/000100683726000019/hchc-20260331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001006837-26-000019
- JSON: https://secwatch.observer/filing/0001006837-26-000019.json
- Plain text: https://secwatch.observer/filing/0001006837-26-000019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.